POST HOC ANALYSIS OF PATIENT AND TREATMENT CHARACTERISTICS BY VONOPRAZAN TREATMENT DURATION: RESULTS FROM PATIENTS WITH REFLUX OESOPHAGITIS IN THE VIEW STUDY
Author(s)
Yinglian Xiao, MD, PhD1, Wensheng Pan, MD, PhD2, Hong Xu, MD, PhD3, Kailun Liang, MD4, Li Xie, MD4, Minhu Chen, MD, PhD1.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Zhejiang Provincial People's Hospital, Hangzhou, China, 3The First Bethune Hospital of Jilin University, Changchun, China, 4Takeda (China) Holdings Co., Ltd., Shanghai, China.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Zhejiang Provincial People's Hospital, Hangzhou, China, 3The First Bethune Hospital of Jilin University, Changchun, China, 4Takeda (China) Holdings Co., Ltd., Shanghai, China.
OBJECTIVES: Reflux oesophagitis (RE) management remains challenging with various factors influencing treatment outcomes. Vonoprazan, a potassium-competitive acid blocker, is approved in China for the treatment of RE. The impact of patient and treatment characteristics on the duration of vonoprazan therapy in patients with RE remains unclear. This post hoc analysis evaluated whether baseline demographics, patient characteristics, concomitant medications, and treatment duration with previous medications influenced vonoprazan treatment duration.
METHODS: VIEW (NCT04501627) was a multicentre, single-arm, prospective, observational, real-world study in China. Patients received 20 mg vonoprazan orally once daily for 4 weeks or 8 weeks (insufficient healing) and were followed up for safety for 2 weeks.
RESULTS: In the RE safety population (n=1877; mean [standard deviation] age=49.7 [13.4] years and body mass index=24.1 [3.5] kg/m2; male=64.4%), 18.9% were current smokers and 7.2% were former smokers. Factors that had a significant impact on vonoprazan treatment duration (4 weeks vs 8 weeks) included mean age (49.3 vs 51.1 years, P=0.011); Los Angeles classification A/B/C/D (43.3%/26.2%/4.4%/1.1% vs 35.1%/32.9%/11.1%/4.6%, P<0.001); oesophageal ulceration (11.2% vs 17.8%, P<0.001); Helicobacter pylori-positive status (13.7% vs 9.1%, P=0.024), hypertension (13.0% vs 18.5%, P=0.003), and heartburn or regurgitation (71.7% vs 78.8%, P=0.003) at enrolment; and mean total Gastroesophageal Reflux Disease Questionnaire score at baseline (8.3 vs 8.8, P=0.003). While concomitant use of proton pump inhibitors (PPIs; 6.6% vs 3.6%, P=0.018) and mucosal protective agents (13.6 vs 8.7, P=0.006) significantly affected vonoprazan treatment duration, the duration of treatment with previous medications (PPIs, H2 receptor antagonists, gastroprokinetic agents, and others) did not.
CONCLUSIONS: In patients with RE, baseline demographics, patient characteristics, and concomitant medications influenced vonoprazan treatment duration, whereas the duration of treatment with previous medications did not.
METHODS: VIEW (NCT04501627) was a multicentre, single-arm, prospective, observational, real-world study in China. Patients received 20 mg vonoprazan orally once daily for 4 weeks or 8 weeks (insufficient healing) and were followed up for safety for 2 weeks.
RESULTS: In the RE safety population (n=1877; mean [standard deviation] age=49.7 [13.4] years and body mass index=24.1 [3.5] kg/m2; male=64.4%), 18.9% were current smokers and 7.2% were former smokers. Factors that had a significant impact on vonoprazan treatment duration (4 weeks vs 8 weeks) included mean age (49.3 vs 51.1 years, P=0.011); Los Angeles classification A/B/C/D (43.3%/26.2%/4.4%/1.1% vs 35.1%/32.9%/11.1%/4.6%, P<0.001); oesophageal ulceration (11.2% vs 17.8%, P<0.001); Helicobacter pylori-positive status (13.7% vs 9.1%, P=0.024), hypertension (13.0% vs 18.5%, P=0.003), and heartburn or regurgitation (71.7% vs 78.8%, P=0.003) at enrolment; and mean total Gastroesophageal Reflux Disease Questionnaire score at baseline (8.3 vs 8.8, P=0.003). While concomitant use of proton pump inhibitors (PPIs; 6.6% vs 3.6%, P=0.018) and mucosal protective agents (13.6 vs 8.7, P=0.006) significantly affected vonoprazan treatment duration, the duration of treatment with previous medications (PPIs, H2 receptor antagonists, gastroprokinetic agents, and others) did not.
CONCLUSIONS: In patients with RE, baseline demographics, patient characteristics, and concomitant medications influenced vonoprazan treatment duration, whereas the duration of treatment with previous medications did not.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO134
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Gastrointestinal Disorders